UA82612C2 - Способ патогенетического лечения гиперхолестеринемии - Google Patents
Способ патогенетического лечения гиперхолестеринемии Download PDFInfo
- Publication number
- UA82612C2 UA82612C2 UAA200613133A UAA200613133A UA82612C2 UA 82612 C2 UA82612 C2 UA 82612C2 UA A200613133 A UAA200613133 A UA A200613133A UA A200613133 A UAA200613133 A UA A200613133A UA 82612 C2 UA82612 C2 UA 82612C2
- Authority
- UA
- Ukraine
- Prior art keywords
- treatment
- hypercholesterinemia
- pathogenetic
- pathogenetic treatment
- hepabene
- Prior art date
Links
- 230000001717 pathogenic effect Effects 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 208000006454 hepatitis Diseases 0.000 abstract description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract description 2
- 240000008042 Zea mays Species 0.000 abstract description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract description 2
- 235000005822 corn Nutrition 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 239000000600 sorbitol Substances 0.000 abstract description 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 240000008530 Rosa canina Species 0.000 abstract 1
- 235000000539 Rosa canina Nutrition 0.000 abstract 1
- 235000010337 Rosa dumalis Nutrition 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000003532 hypothyroidism Diseases 0.000 description 3
- 230000002989 hypothyroidism Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 239000000731 choleretic agent Substances 0.000 description 2
- 230000001989 choleretic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- MSYQJZMDTZWNQZ-UHFFFAOYSA-N 2-[(5-methyl-1h-1,2,4-triazol-3-yl)sulfanyl]acetic acid;morpholine Chemical compound C1COCC[NH2+]1.CC1=NC(SCC([O-])=O)=NN1 MSYQJZMDTZWNQZ-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-UHFFFAOYSA-N 6,18-dimethoxy-17-[oxo-(3,4,5-trimethoxyphenyl)methoxy]-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid methyl ester Chemical compound C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 101100533283 Dictyostelium discoideum serp gene Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 230000002930 anti-sclerotic effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001553 hepatotropic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Изобретение относится к медицине, в частности к способу патогенетического лечения гиперхолестеринемии. Больным проводят 2-3 курса слепых зондирований сорбитом на фоне приема отваров плодов шиповника и кукурузных рылец, гепатопротекторов - карсила (гепабене, силимарол). При наличии хронического гепатита, цирроза печени разной этиологии добавляют эссенциале форте и тиотриазолин.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA200613133A UA82612C2 (ru) | 2006-12-12 | 2006-12-12 | Способ патогенетического лечения гиперхолестеринемии |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA200613133A UA82612C2 (ru) | 2006-12-12 | 2006-12-12 | Способ патогенетического лечения гиперхолестеринемии |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA82612C2 true UA82612C2 (ru) | 2008-04-25 |
Family
ID=39819085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200613133A UA82612C2 (ru) | 2006-12-12 | 2006-12-12 | Способ патогенетического лечения гиперхолестеринемии |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA82612C2 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2462251C1 (ru) * | 2011-04-11 | 2012-09-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет имени И.И. Мечникова" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО СЗГМУ им. И.И.Мечникова Минздравсоцразвития Рос | Способ лечения больных хроническими заболеваниями печени с латентной стадией и i степенью клинически выраженной стадии печеночной энцефалопатии |
-
2006
- 2006-12-12 UA UAA200613133A patent/UA82612C2/ru unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2462251C1 (ru) * | 2011-04-11 | 2012-09-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет имени И.И. Мечникова" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО СЗГМУ им. И.И.Мечникова Минздравсоцразвития Рос | Способ лечения больных хроническими заболеваниями печени с латентной стадией и i степенью клинически выраженной стадии печеночной энцефалопатии |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Frenette et al. | Emricasan improves liver function in patients with cirrhosis and high model for end-stage liver disease scores compared with placebo | |
| Lan et al. | Recreational nitrous oxide abuse related subacute combined degeneration of the spinal cord in adolescents–a case series and literature review | |
| Rosenblum et al. | A progressive neurologic syndrome in children with chronic liver disease | |
| Robinson et al. | Meta-analysis of the relationship between non–high-density lipoprotein cholesterol reduction and coronary heart disease risk | |
| Askarpour et al. | Efficacy of l-carnitine supplementation for management of blood lipids: A systematic review and dose-response meta-analysis of randomized controlled trials | |
| Safeer et al. | Cholesterol treatment guidelines update | |
| Bansal et al. | Orlistat | |
| Tomeno et al. | Emerging drugs for non-alcoholic steatohepatitis | |
| Lee et al. | Effect of nucleos (t) ide analogue therapy on risk of intrahepatic cholangiocarcinoma in patients with chronic hepatitis B | |
| Sinakos et al. | Serum lipids in primary sclerosing cholangitis | |
| Maevskaya et al. | Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy | |
| Purva et al. | A review on dyslipidemia: types, risk factors and management | |
| UA82612C2 (ru) | Способ патогенетического лечения гиперхолестеринемии | |
| Bergmann et al. | Jaundice due to suspected statin hepatotoxicity: a case series | |
| Dyball et al. | The underlying mechanisms by which PTSD symptoms are associated with cardiovascular health in male UK military personnel: The ADVANCE cohort study | |
| Durham et al. | Hepatotoxicity upon using niacin to pass a drug test: A case report | |
| Weissfeld et al. | Cerebrotendinous Xanthomatosis ataxia responsive to CDCA and Riluzole | |
| Neuman et al. | Multiple factors involved in nonalcoholic hepatitis pathogenesis | |
| Fekaj et al. | The effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment: a prospective, randomized, and controlled study | |
| Mateu de Antonio et al. | Multicenter study of parenteral nutrition in non-critically ill elderly patients compared to younger patients-Study IAIOS-PN (Incidence and Assessment of latrogenesis in Older Subjects receiving Parenteral Nutrition) | |
| Nikalji et al. | Rosuvastatin-induced rhabdomyolysis: a case report | |
| Bratton et al. | Prolonged jaundice secondary to amiodarone use: a case report and literature review | |
| Kuver | The effects of statins on cholestasis: good, bad or indifferent? | |
| Zhang et al. | Fatal hepatotoxicity due to viaminate | |
| Khan et al. | Effect of Concurrent Use of Herbal Supplements and Prescribed Drugs in Chronic Diseases. |